Skip to main content
. Author manuscript; available in PMC: 2009 Sep 15.
Published in final edited form as: J Urol. 2008 Mar;179(3):1178–1183. doi: 10.1016/j.juro.2007.10.030

Fig. 2.

Fig. 2

Effect of intrathecal application of muscimol (black bars; 0.001–0.1 μg) or baclofen (white bars; 0.001–1 μg) on the number (A) and amplitude (B) of NVCs, as well as the MVP (C) in SCI rats. Measurements after drugs were compared with the values before drug application (control). A: The number of NVCs was significantly decreased by intrathecal application of 0.1 μg of muscimol or baclofen (0.1–1 μg). B: The amplitude of NVCs was significantly and dose-dependently decreased after intrathecal application of muscimol (0.01–0.1 μg) or baclofen (0.01–1 μg). C: The MVP was significantly and dose-dependently decreased after intrathecal application of musimol (0.01–0.1 μg) or 1 μg of baclofen. Values are the mean ± standard error (SE). Significant difference from control (Cont): * p < 0.05, and ** p < 0.01. Increasing doses of drugs were administered at 15–30 min intervals.